Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582754 | 0.94 | HTR2A (0.47) | MGLLMEN1KMT2AKCNH2LMNA | |
| SCHEMBL1582914 | 0.92 | POLB (0.53) | MGLLLMNAHSD11B1 | |
| SCHEMBL1583136 | 0.90 | MGLL (0.51) | MGLLMEN1KMT2ALMNAHSD11B1 | |
| SCHEMBL1583000 | 0.89 | MEN1 (0.51) | MGLLMEN1KMT2AKCNH2LMNA | |
| SCHEMBL1582768 | 0.85 | HSD11B1 (0.50) | MGLLKCNH2LMNAHSD11B1 | |
| SCHEMBL1582543 | 0.82 | MGLL (0.57) | MGLLLMNAHSD11B1 | |
| SCHEMBL12721473 | 0.82 | MGLL (0.54) | MGLLMEN1KMT2AKCNH2LMNA | |
| SCHEMBL1582920 | 0.81 | HSD11B1 (0.51) | MEN1KMT2ALMNAHSD11B1 | |
| SCHEMBL1582856 | 0.77 | HSD11B1 (0.54) | LMNAHSD11B1 | |
| SCHEMBL1582926 | 0.77 | HSD11B1 (0.53) | MGLLHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546100-B1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK HOLDINGS CO LTD (KR) | 2011-04-20 | — | — | EP | disclosed |
| EP-1546100-A1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK Corporation (KR) | 2005-06-29 | — | — | EP | disclosed |
| US-6770659-B2 | Benzoyl piperidine compounds | SK CORPORATION (KR) | 2004-08-03 | — | — | US | disclosed |
| WO-2004018423-A1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK CORPORATION (KR) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018423-A1 | NEW BENZOYL PIPERIDINE COMPOUNDS | SK CORPORATION (KR) | 2004-03-04 | — | — | WO | disclosed |
| US-20040044033-A1 | New benzoyl piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044033-A1 | New benzoyl piperidine compounds | GABRE, GRIN2C, GRIN1 | MGLL 4147/4885MEN1 3741/4885KMT2A 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.